Press release
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
– Company to Host Conference Call on August 30, 2024, at 1:00 p.m. (BST), 8:00 a.m. (ET) to Discuss Results – CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Company to Host Conference Call on August 30, 2024, at 1:00 p.m. (BST), 8:00 a.m. (ET) to Discuss Results –\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present results from the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy at the European Society of Cardiology (ESC) Congress 2024, taking place in London, UK, on August 30 - September 2, 2024. The Company recently announced positive topline results of the study which met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events, as well as all secondary endpoints, in both the overall population and in the monotherapy population, along with an acceptable safety profile and tolerability, consistent with its established profile. The Company will also host an Investor Webcast to discuss the HELIOS-B results on August 30, 2024. Vutrisiran is in development for the treatment of ATTR amyloidosis with cardiomyopathy.\n\n\nIn addition, the Company will present findings from a subgroup analysis of the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension, as well as new data from post-hoc analyses of the APOLLO-B Phase 3 and APOLLO-OLE studies of patisiran in patients with ATTR amyloidosis with cardiomyopathy. Patisiran is not approved for the treatment of ATTR amyloidosis with cardiomyopathy.\n\n\nESC Presentation Details\n\n\n\nPrimary Results from HELIOS-B, a Phase 3 Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy\nLondon: Hot Line 1\nFriday, August 30, 2024, 11:00 a.m. (BST), 6:00 a.m. (ET)\nPresenter: Marianna Fontana, M.D., Ph.D.\n\n\n\n\n\nSubgroup Results from KARDIA-2: Impact of Demographic and Baseline Disease Characteristics on Zilebesiran Response in Patients with Hypertension Uncontrolled by a Standard Oral Antihypertensive\nScience Box 4: Pharmacological Management in Hypertension\nFriday, August 30, 2024, 2:30 p.m. (BST), 9:30 a.m. (ET)\nPresenter: Manish Saxena, MBBS, MSc, FBHS\n\n\n\n\n\nLong-term Effects of Patisiran on Survival and Cardiac Parameters in Patients with Transthyretin-Mediated Cardiac Amyloidosis: ...